Type to search

Gracell Biotechnologies to Present Preclinical Results of TruUCAR-enabled CD19/CD7 Dual-Directed Allogeneic CAR-T Cell Therapy at 63rd ASH Annual Meeting | Pharmtech Focus
Gracell Biotechnologies Signs Exclusive License Agreement with FutureGen Biopharm to Develop Engineered Immune Cell Therapies Targeting Claudin 18.2 in Solid Tumors | Pharmtech Focus